<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356486</url>
  </required_header>
  <id_info>
    <org_study_id>CORAL-2</org_study_id>
    <secondary_id>2004 - 000907 -16</secondary_id>
    <nct_id>NCT00356486</nct_id>
  </id_info>
  <brief_title>Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV</brief_title>
  <official_title>Open, Multicentre and Randomised Phase IV Study to Evaluate Viral Kinetics in the First 12 Weeks of Patients With Chronic Hepatitis C Genotypes 1 and 4 Coinfected by the Human Immunodeficiency Virus Treated With Induction Doses of Peginterferon Alpha-2a (40 KD) (270 μg/Week) and Ribavirin (1600 mg/Day) With Epoetin β Support (450 IU/kg/Week)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the early virological response (EVR = undetectable
      [ribonucleic acid-hepatitis C virus] RNA-HCV or a reduction of &gt; 2 log10) of patients with
      chronic hepatitis C coinfected with HIV treated with induction doses of peginterferon
      alpha-2a (40 KD) 270 µg/week and ribavirin 1600 mg/day for 4 weeks, followed by 8 weeks of
      treatment with peginterferon alpha-2a (40 KD) 180 µg/week and ribavirin 1000-1200 mg/day
      versus treatment with peginterferon alpha-2a (40 KD) 180 µg/week and ribavirin 1000-1200
      mg/day for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to ascertain whether treatment with higher doses of PEGASYS (270 µg/week)
      and ribavirin (1600 mg/day) for the first four weeks achieves the plasma concentrations of
      the product in the blood needed to reduce the half-life of the virions and accelerate the
      elimination thereof. This would bring the viral kinetic curves in coinfected patients closer
      to the model described for mono-infected HCV patients, probably achieving improved rates of
      response in week 12 (early virological response) and posterior in week 72 (sustained
      virological response).

      Therefore, the patients were randomised to treatment with two different doses, 270 µg and 180
      µg of PEGASYS, and 1600 mg and 1000-1200 mg of ribavirin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with undetectable RNA-HCV</measure>
    <time_frame>at week 12 after starting treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variations of the levels of RNA-HCV</measure>
    <time_frame>from baseline until weeks 4, 8, and 12 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with undetectable HCV RNA</measure>
    <time_frame>in weeks 4 and 8 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of ALT</measure>
    <time_frame>At weeks 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that must reduce the dose of peginterferon alpha-2a (40 KD) and ribavirin.</measure>
    <time_frame>During the 12 weeks of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that drop out of the study for adverse effects or intolerance</measure>
    <time_frame>During the 12 weeks of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in levels of haemoglobin, neutrophil, and platelet count</measure>
    <time_frame>at 4, 8, and 12 weeks with regard to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AIDS-defining events or death</measure>
    <time_frame>During the 12 weeks of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the CD4/CD8 cell count</measure>
    <time_frame>At 4, 8, and 12 weeks of follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferon alfa-2a (40 KD) (270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (40 KD) (180 µg/week) + Ribavirin (1000-1200 mg/day) for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a, Ribavirin, epoetin-β</intervention_name>
    <description>Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a + Ribavirin for 12 weeks</intervention_name>
    <description>Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serological evidence of chronic hepatitis C infection in an anti-HCV antibody test

          -  Detectable RNA-HCV plasma level genotype 1 and 4

          -  ALT serum activity above the upper limit of normality

          -  Chronic liver disease consistent with chronic hepatitis C infection in a biopsy
             obtained during the two years prior to inclusion in the study

          -  Serological evidence of HIV-1 infection, diagnosed by Enzyme-Linked Immunosorbent
             Assay (ELISA) and confirmed by Western-blot.

          -  Patients with CD4 cell count &gt; 200 /µl

          -  Stable status in HIV-1 infection, in the investigator's opinion, in other words,
             patients that are not expected to progress during the study.

          -  Patients treated with stable anti-retroviral therapy (HAART), which does not include
             nucleoside analogues, for at least 6 weeks before the baseline assessment

          -  Patients that do not receive HAART therapy

          -  Negative pregnancy test in urine or blood

        Exclusion Criteria:

          -  Women currently pregnant or in the lactation period.

          -  Patients whose companion is pregnant.

          -  Therapy with interferon (IFN) or ribavirin at any previous time.

          -  Patients with cirrhosis in the hepatic biopsy.

          -  Documented suspicion by ultrasound of hepatocarcinoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonaventura Clotet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LLuita contra la Sida Foundation-HIV Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol, Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Vic</name>
      <address>
        <city>Vic</city>
        <state>Barcelona</state>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Donostia</state>
        <zip>20012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón.</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2006</study_first_posted>
  <last_update_submitted>September 2, 2009</last_update_submitted>
  <last_update_submitted_qc>September 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Lluita Sida Foundation</name_title>
    <organization>Lluita Sida Foundation</organization>
  </responsible_party>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Co-infection</keyword>
  <keyword>Induction dose</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

